We previously engineered Saccharomyces cerevisiae through CRISPR-Cas9 integration to produce Ply511, a bacteriophage endolysin active against L. monocytogenes, showing the potential of engineered yeast to produce endolysins for biocontrol. In this study, we extended this approach to the probiotic yeast S. boulardii and directly compared the two yeasts as secretion hosts for Ply511. Using a simulated human gastrointestinal environment, we evaluated their ability to retain endolysin activity and reduce L. monocytogenes levels.
New paper from the CEB- @uminho.bsky.social & APC
๐๐ฏ๐๐ฅ๐ฎ๐๐ญ๐ข๐จ๐ง ๐จ๐ ๐ญ๐ก๐ ๐๐๐ฅ๐ข๐ฏ๐๐ซ๐ฒ ๐จ๐ ๐๐ง ๐๐ง๐ญ๐ข-๐๐ข๐ฌ๐ญ๐๐ซ๐ข๐ ๐๐ง๐๐จ๐ฅ๐ฒ๐ฌ๐ข๐ง ๐ฏ๐ข๐ ๐๐๐๐๐๐-๐๐๐ฌ๐ ๐๐ง๐ ๐ข๐ง๐๐๐ซ๐๐ ๐ฉ๐ซ๐จ๐๐ข๐จ๐ญ๐ข๐ ๐บ๐๐๐๐๐๐๐๐๐๐๐๐ ๐๐๐๐๐๐๐
๐๐
Appl Microbiol Biotechnol buff.ly/pDDfR3f
#CRISPRCas9
@ellen-murr.bsky.social @rioscolombo.bsky.social @colinhillucc.bsky.social